Decoy Therapeutics (DCOY): CEO Rick Pierce on the Company’s Groundbreaking Approach to Drug Development in the AI/ML Era
Artikel konnten nicht hinzugefügt werden
Der Titel konnte nicht zum Warenkorb hinzugefügt werden.
Der Titel konnte nicht zum Merkzettel hinzugefügt werden.
„Von Wunschzettel entfernen“ fehlgeschlagen.
„Podcast folgen“ fehlgeschlagen
„Podcast nicht mehr folgen“ fehlgeschlagen
Decoy Therapeutics (DCOY): CEO Rick Pierce on the Company’s Groundbreaking Approach to Drug Development in the AI/ML Era
-
Gesprochen von:
-
Von:
Über diesen Titel
In this episode of the WTR Healthcare Happenings podcast, Tim Gerdeman, Vice Chair, Co-Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR’s Healthcare Research Analyst, speak with Rick Pierce, CEO of Decoy Therapeutics (NASDAQ: DCOY). The conversation explores Decoy’s innovative business model for developing peptide‑conjugate antivirals designed to target multiple respiratory viruses. Pierce explains how Decoy is navigating the modern era of drug development with a cost‑effective, highly efficient strategy that positions the company as a disruptive force in biotech. Central to this approach is Decoy’ proprietary peptide‑synthesis technology and rapid design‑build‑test cycle, powered by machine learning. He also underscores the importance of Decoy’s strategic partnerships with the Gates Foundation, Google, and NVIDIA in advancing its platform and accelerating development.
